Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse

Table 1 Incidence of clinical characteristics among participants

Total	194
Gender, n (%)
Male	99 (51)
Female	95 (49)
Extent of disease, n (%)
Pancolitis	125 (64)
Left-side colitis	48 (25)
Proctitis	21 (11)
Median (IQR) age at onset	32 (22-43)
Median (IQR) duration of disease, months	107 (51-194)
Median (IQR) age of undergoing colonoscopy	44 (33-56)
Median (IQR) duration of sustaining clinical remission at the time of colonoscopy, months	11 (6-23)
Concomitant medications, n (%)
Aminosalicylate	178 (92)
Corticosteroids	27 (14)
Mercaptopurine/Azathioprine	79 (41)
Tacrolimus	10 (5)
Biologics	9 (5)
Colonoscopy findings, n (%) (maximum index in the colorectum)
MES 0	94 (49)
MES 1	57 (29)
MES 2	39 (20)
MES 3	4 (2)
Fecal Hb concentrations (ng/mL), n (%)
0-100	111 (57)
101-1000	56 (29)
1001-10000	20 (10)
10001-	7 (4)

MES: Mayo Endoscopic subscore; Hb: Hemoglobin; IQR: Interquartile range.

Table 2 Characteristics of patients with MES 0 vs MES 1-3

Characteristics	MES 0	MES 1-3	P value
	(n = 94)	(n = 100)
Gender, n (%)
Male	54 (57)	45 (45)	0.083
Female	40 (43)	55 (55)
Median age, yr (IQR)	46 (32-60)	41 (33-51)	0.051
Median duration of disease, mo (IQR)	99 (53-198)	112 (44-191)	0.950
Median age at onset, yr (IQR)	34 (22-47)	31 (22-40)	0.130
Median duration of sustaining clinical remission at the time of colonoscopy, mo (IQR)	17 (9-33)	9 (4-13)	< 0.0001
Extent of disease, n (%)
Pancolitis	59 (63)	66 (66)	0.340
Left-side colitis	27 (29)	21 (21)
Proctitis	8 (8)	13 (13)
Concomitant medications, n (%)
Aminosalicylate	86 (91)	92 (92)	0.900
Corticosteroids	11 (12)	16 (16)	0.390
Mercaptopurine/Azathioprine	45 (48)	34 (34)	0.049
Tacrolimus	4 (4)	6 (6)	0.580
Biologics	2 (2)	7 (7)	0.110
Fecal Hb concentrations (ng/mL)	50 (4-50)	315 (108-1277)	< 0.0001

MES: Mayo endoscopic subscore; Hb: Hemoglobin; IQR: Interquartile range.